Molecular characterization of thymidine kinase from Ureaplasma urealyticum:: nucleoside analogues as potent inhibitors of mycoplasma growth

被引:38
作者
Carnrot, C
Wehelie, R
Eriksson, S
Bölske, G
Wang, LY
机构
[1] Swedish Univ Agr Sci, Dept Mol Biosci, Sect Vet Med Biochem, Biomed Ctr, SE-75123 Uppsala, Sweden
[2] Natl Vet Inst, SE-75189 Uppsala, Sweden
关键词
D O I
10.1046/j.1365-2958.2003.03717.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ureaplasma urealyticum (U. urealyticum), belonging to the class Mollicutes, is a human pathogen colonizing the urogenital tract and causes among other things respiratory diseases in premature infants. We have studied the salvage of pyrimidine deoxynucleosides in U. urealyticum and cloned a key salvage enzyme, thymidine kinase (TK) from U. urealyticum. Recombinant Uu-TK was expressed in E. coli, purified and characterized with regards to substrate specificity and feedback inhibition. Uu-TK efficiently phosphorylated thymidine (dThd) and deoxyuridine (dUrd) as well as a number of pyrimidine nucleoside analogues. All natural ribonucleoside/deoxyribonucleoside triphosphates, except dTTP, served as phosphate donors, while dTTP was a feedback inhibitor. The level of Uu-TK activity in U. urealyticum extracts increased upon addition of dUrd to the growth medium. Fluoropyrimidine nucleosides inhibited U. urealyticum and M. pneumoniae growth and this inhibitory effect could be reversed by addition of dThd, dUrd or deoxytetrahydrouridine to the growth medium. Thus, the mechanism of inhibition was most likely the depletion of dTTP, either via a blocked thymidine kinase reaction and/or thymidylate synthesis step and these metabolic reactions should be suitable targets for antimycoplasma chemotherapy.
引用
收藏
页码:771 / 780
页数:10
相关论文
共 37 条
[21]  
MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621
[22]   GROWTH-INHIBITION OF UREAPLASMA-UREALYTICUM BY THE PROTON PUMP INHIBITOR LANSOPRAZOLE - DIRECT ATTRIBUTION TO INHIBITION BY LANSOPRAZOLE OF UREASE ACTIVITY AND UREA-INDUCED ATP SYNTHESIS IN U-UREALYTICUM [J].
NAGATA, K ;
TAKAGI, E ;
SATOH, H ;
OKAMURA, H ;
TAMURA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2187-2192
[23]  
Peters G. J., 1995, OXFORD TXB ONCOLOGY, V1, P524
[24]   FLUOROURACIL - BIOCHEMISTRY AND PHARMACOLOGY [J].
PINEDO, HM ;
PETERS, GFJ .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1653-1664
[25]  
Pollack J. Dennis, 2002, OMICS A Journal of Integrative Biology, V6, P247, DOI 10.1089/15362310260256909
[26]  
Pollack JD, 2001, TRENDS MICROBIOL, V9, P169, DOI 10.1016/S0966-842X(01)01950-3
[27]   Molecular biology and pathogenicity of mycoplasmas [J].
Razin, S ;
Yogev, D ;
Naot, Y .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1998, 62 (04) :1094-+
[28]  
Regula JT, 2000, ELECTROPHORESIS, V21, P3765, DOI 10.1002/1522-2683(200011)21:17<3765::AID-ELPS3765>3.0.CO
[29]  
2-6
[30]   INTERACTIONS BETWEEN DEOXYRIBONUCLEOTIDE AND DNA-SYNTHESIS [J].
REICHARD, P .
ANNUAL REVIEW OF BIOCHEMISTRY, 1988, 57 :349-374